REGN vs INCY — Key Metrics

Metric REGN (REGENERON PHARMACEUTICALS INC) INCY (INCYTE CORP)
Price945.53117.8
Market Cap97.81 Billion24.01 Billion
P/E (TTM)20.1156.36
P/B (Quarterly)2.8654.219
P/S (TTM)5.793.99
Net Profit Margin (TTM)28.56.7
Gross Margin (TTM)85.892.7
ROE (TTM)15.17.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

REGENERON PHARMACEUTICALS INC
vs
 
INCYTE CORP
 
REGENERON PHARMACEUTICALS INC
vs
 
INCYTE CORP
Performance Comparison
AI Model Recommendation
REGN · REGENERON PHARMACEUTICALS INC

Outperform

60
UnderperformOutperform
INCY · INCYTE CORP

Greatly Outperform

84
UnderperformOutperform
Recommendation Summary

Stock REGN is projected to outperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.

Financial Metrics
Prices delayed ~15 min
REGN Metrics INCY
$945.53 Price $117.80
— Market Capitalization —
20.11 Price to Earnings Ratio 56.36
5.79 Price to Sales 3.99
25.56 Price to FCF Ratio 35.06
6.75 Price to Gross Profit 4.31
14.83 Price to R&D 6.99
4.7 Price to Current Assets 4.35

REGN vs INCY at a glance

Regeneron Pharmaceuticals INC (REGN) and Incyte Corp (INCY) are both Biotechnology companies in the Healthcare sector. REGN is the larger, at $97.8 billion in market value against $24.0 billion for INCY, about 4.1 times the size.

On trailing-twelve-month figures, REGN trades at 20.1 times trailing earnings and INCY at 56.4; net profit margins are 28.5% and 6.7%.

The Upfront Investment model currently rates REGN Outperform and INCY Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.